Compare Enveric Biosciences Inc (ENVB) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs IQIYI Inc - ADR — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while IQIYI Inc - ADR trades at $1.02 (market cap $979.50M). The key difference: IQIYI Inc - ADR is far larger — about 146.4× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 1,962,950). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and IQIYI Inc - ADR for 55 Days on average.
| ENVB | IQ | |
|---|---|---|
Market Cap | $6.69M | $979.50M |
Volume | 41,141 | 1,962,950 |
Sector | Health | Media |
52-Week High | $10.80 | $2.35 |
52-Week Low | $1.27 | $0.86 |
Typical Hold Time | 14 Days | 55 Days |
Enterprise Value | -$1.60M | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
IQ trades at $1.015, up 0.5% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $206.31 million in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29 billion, and negative profit margins persist. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights iQIYI's focus on AI-driven content, including new titles and revenue-sharing successes.
The outlook is cautious due to revenue contraction and recurring losses, though AI initiatives offer growth potential. Key risks include competitive pressures in streaming and reliance on Chinese market dynamics. Institutional ownership trends and earnings performance in upcoming quarters will be critical for stock direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
